Molecular Epidemiology of Enteroviruses Detected at the Virology Laboratory of Brest University Hospital During the Period 2018-2024: Retrospective Analysis of an Atypical Meningitis Epidemic in 2024 (BrEcho9Men)

Active, not recruiting

• Conditions: Enterovirus Infections; Meningitis, Viral; Meningitis Enterovirus; Echovirus 9

• Registration Number: NCT06922474
• Lead Sponsor: University Hospital, Brest

Brief Summary

This study is being done to learn more about enterovirus infections detected in the cerebrospinal fluid of patients at CHU de Brest. Researchers will analyze medical records and laboratory data collected between 2018 and 2024. They will look at how these infections present in patients, and whether a specific virus type, called Echo-9, may be associated with different clinical features or represent an emerging variant.

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-03
• Study Start: 2025-03-01
• Study First Submitted: 2025-04-03
• Study First Submitted QC: 2025-04-03
• Last Update Submitted: 2025-04-03
• Study First Posted: 2025-04-10
• Last Update Posted: 2025-04-10
• Primary Completion: 2025-10-31
• Study Completion: 2025-10-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

• Cerebrospinal fluid (CSF) sample positive for enterovirus by RT-PCR between January 1, 2018 and December 31, 2024 , performed at the virology laboratory of CHU de Brest.
• No documented opposition to the use of medical data for research purposes.

Exclusion Criteria

• Patients under legal protection (guardianship, curatorship, etc.)
• Refusal to participate in the study

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Phylogenetic analysis of Echo-9 strains detected between 2018 and 2024	January 1, 2018 to December 31, 2024	Molecular characterization and phylogenetic comparison of Echo-9 strains detected at CHU de Brest and throughout France between January 1, 2018 and December 31, 2024, to identify a possible emerging variant.

Secondary Outcome Measures

Name	Time	Method
Temporal distribution of enterovirus infections documented at CHU de Brest	January 1, 2018 to December 31, 2024	Weekly quantification of enterovirus-positive cases (by RT-PCR) detected at CHU de Brest from 2018 to 2024. Comparison with national surveillance data from the French National Reference Center to detect atypical epidemic peaks, with a focus on 2024.
Clinical characteristics of enterovirus-positive CSF cases	January 1, 2018 to December 31, 2024	Among patients with cerebrospinal fluid samples positive for enterovirus between 2018 and 2024, clinical features will be described, including headache intensity, clinical severity, infection site (CSF, throat, stool, nasopharyngeal samples), and use of morphine. Subgroup comparisons may be conducted according to enterovirus genotype and year of infection, depending on the results of molecular typing.
Biological characteristics of enterovirus-positive CSF samples	January 1, 2018 to December 31, 2024	Among patients with cerebrospinal fluid samples positive for enterovirus between 2018 and 2024, biological parameters from positive samples will be described. For cerebrospinal fluid samples, variables include white blood cell count with differential, protein level, and the cerebrospinal fluid to blood glucose ratio. The presence or absence of additional positive samples (throat, stool, nasopharyngeal swabs) will also be documented.

Trial Locations

Locations (1)

Chu Brest; 🇫🇷 Brest, France